

265 **Table S1. Clinical characteristics of the five patients with COVID-19 and secondary bacterial co-infection**

Patients	Age	Sex	Ward	Organisms (s)	Comorbidity	Charlson index	Invasive procedures	Time from ICU admission to bacterial infection onset, (days)	Time from MV start to bacterial infection onset, (days)	Antiviral treatment
1	66	F	ICU	<i>E. coli</i> , <i>B. cepacia</i>	None	2	MV, ECMO	13	13	Arbidol+ lopinavir/ritonavir
2	90	M	ICU	<i>K. pneumoniae</i>	CHD, FL, CKD	13	MV, ECMO	6	2	Arbidol+ lopinavir/ritonavir+ interferon alpha inhalation
3	59	M	ICU	<i>C. albicans</i> , <i>P. aeruginosa</i> , <i>A. fumigatus</i>	Post status of liver transplantation	4	MV, ECMO, BAL	9	7	Arbidol+ lopinavir/ritonavir+ interferon alpha inhalation
4	70	M	ICU	<i>S. maltophilia</i>	Hypertension, Diabetes	4	MV, ECMO	9	4	Arbidol+Darunavir
5	62	M	ICU	<i>B. cepacia</i>	Hypertension, Colon cancer	4	MV	18	17	Arbidol+ lopinavir/ritonavir

266 Abbreviation: F, female; M, male; ICU, intensive care unit; CHD, coronary heart disease; FL, fatty liver; CKD, chronic kidney disease; MV,

267 mechanical ventilation; ECMO, extra-corporeal membrane oxygenation; BAL, bioartificial liver.

268 *E. coli* = *Escherichia coli*, *B. cepacia* = *Burkholderia cepacia*, *K. pneumoniae* = *Klebsiella pneumoniae*, *P. aeruginosa* = *Pseudomonas*

269 *aeruginosa*, *C. albicans* = *Candida albicans*, *A. fumigatus* = *Aspergillus fumigatus*, *S. maltophilia* = *Stenotrophomonas maltophilia*.